Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.67 |
| ▸ | CA2 | P00918 | 7/20 | 0.67 |
| ▸ | CA12 | O43570 | 6/20 | 0.67 |
| ▸ | CA9 | Q16790 | 4/20 | 0.67 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.64 |
| ▸ | CA7 | P43166 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | CA5A | P35218 | 2/20 | 0.61 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.58 |
| ▸ | CA4 | P22748 | 2/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30958759 | 0.88 | POLB (0.68) | CA1CA2CA12CA9CA14 | |
| SCHEMBL31398260 | 0.80 | CA1 (0.68) | CA1CA2CA12CA9CA14 | |
| SCHEMBL3367299 | 0.79 | PRMT1 (0.54) | CA12CA9CA14CA7HSD17B10 | |
| SCHEMBL15672851 | 0.79 | MEN1 (0.58) | HSD17B10PRMT1ALDH1A1LMNACYP3A4 | |
| SCHEMBL4520702 | 0.79 | POLB (0.79) | CA12CA9CA14CA7HSD17B10 | |
| SCHEMBL4601440 | 0.79 | CA1 (0.59) | CA1CA2HSD17B10PRMT1ALDH1A1 | |
| SCHEMBL1168754 | 0.79 | ALDH1A1 (0.63) | CA12CA9CA14CA7HSD17B10 | |
| SCHEMBL21034352 | 0.79 | TAAR1 (0.59) | CA12CA9CA14CA7HSD17B10 | |
| SCHEMBL49549 | 0.78 | CA2 (1.00) | CA1CA2CA12CA9CA14 | |
| SCHEMBL412302 | 0.78 | ALDH1A1 (0.79) | CA1CA2HSD17B10PRMT1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0034432-B1 | SULFAMOYL-SUBSTITUTED PHENETHYLAMINE DERIVATIVES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS, CONTAINING THEM | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1984-04-25 | — | — | EP | claimed |
| EP-2661436-B1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2016-04-13 | — | — | EP | disclosed |
| EP-2661436-B1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | LEO PHARMA AS (DK) | 2016-04-13 | — | — | EP | disclosed |
| US-9233964-B2 | Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof | LEO PHARMA A/S (DK) | 2016-01-12 | — | — | US | disclosed |
| US-9233964-B2 | Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof | LEO PHARMA A/S (DK) | 2016-01-12 | — | — | US | disclosed |
| US-9233964-B2 | Sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use therof | LEO PHARMA A/S (DK) | 2016-01-12 | — | — | US | disclosed |
| US-20130345194-A1 | SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS | LEO PHARMA A/S (DK) | 2013-12-26 | — | — | US | disclosed |
| EP-2661436-A1 | NOVEL SULFAMIDE PIPERAZINE DERIVATIVES AS PROTEIN TYROSINE KINASE INHIBITORS AND PHARMACEUTICAL USE THEREOF | Leo Pharma A/S (DK) | 2013-11-13 | — | — | EP | disclosed |
| CN-103298817-A | Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof | LEO PHARMA AS | 2013-09-11 | — | — | CN | disclosed |
| US-8299021-B2 | Macrocyclic inhibitors of hepatitis C virus replication | INTERMUNE, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| CN-1816523-A | N-(2-phenylethyl)sulfamide derivatives as integrin alpha4 antagonists | ALMIRALL PRODESFARMA SA (ES) | 2006-08-09 | — | — | CN | disclosed |
| EP-1622867-A1 | N-(2-PHENYLETHYL)SULFAMIDE DERIVATIVES AS INTEGRIN ALPHA4 ANTAGONISTS | Almirall Prodesfarma, S.A. (ES) | 2006-02-08 | — | — | EP | disclosed |
| WO-2005075415-A1 | A METHOD OF PREPARATION OF (R)-(-)-5(2-AMINOPROPYL)-2-METHOXYBENZENESULFONAMIDE | ZENTIVA, A.S. (CZ) | 2005-08-18 | — | — | WO | disclosed |
| WO-2005063701-A1 | SYNTHESIS OF OPTICALLY PURE (R)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULPHONAMIDE | LEK PHARMACEUTICALS D.D. (CH) | 2005-07-14 | — | — | WO | disclosed |
| WO-2004099126-A1 | N-(2-PHENYLETHYL)SULFAMIDE DERIVATIVES AS INTEGRIN α4 ANTAGONISTS | ALMIRALL PRODESFARMA SA (ES) | 2004-11-18 | — | — | WO | disclosed |
| WO-2003035608-A1 | A METHOD OF THE PREPARATION OF (R)-(-)-5`2-`2-(2-ETHOXYPHENOXY) ETHYLAMINO! PROPYL!-2-METHOXYBENZENESULPHONAMIDE (TAMSULOSIN) | LECIVA, A.S. (CZ) | 2003-05-01 | — | — | WO | disclosed |
| EP-0805812-B1 | BICYCLIC SUBSTITUTED HEXAHYDROBENZ(E)ISOINDOLE ALPHA-1- ADRENERGIC ANTAGONISTS | ABBOTT LAB (US) | 2001-06-13 | — | — | EP | disclosed |
| EP-0749302-A4 | HYDROXAMIC ACID AND CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE THEREOF | SANOFI WINTHROP INC (US) | 1999-08-25 | — | — | EP | disclosed |
| EP-0749302-A1 | HYDROXAMIC ACID AND CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE THEREOF | SANOFI WINTHROP, INC. (US) | 1996-12-27 | — | — | EP | disclosed |
| WO-1995022966-A1 | HYDROXAMIC ACID AND CARBOXYLIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND USE THEREOF | SANOFI WINTHROP, INC. (US) | 1995-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345194-A1 | SUBSTITUTED CYCLOPENTYL-AZINES AS CASR-ACTIVE COMPOUNDS | JAK1, CNKSR1, TSHR | CA1 506/4885CA2 1068/4885CA12 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.